• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Beam Therapeutics Appoints Leading Healthcare Executive Kate Walsh to its Board of Directors

    1/11/21 6:30:00 AM ET
    $BEAM
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $BEAM alert in real time by email

    CAMBRIDGE, Mass., Jan. 11, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that Kate Walsh, president and chief executive officer of the Boston Medical Center (BMC) health system, has joined the company’s board of directors. BMC is a private, not-for-profit, academic medical center with a community-based focus and is the primary teaching affiliate of Boston University School of Medicine.

    “Kate is an exceptional leader with an impressive track record of leading complex and highly successful healthcare organizations of all sizes, and we are thrilled to welcome her to our board,” said John Evans, chief executive officer of Beam Therapeutics. “Beam made tremendous progress across our portfolio in 2020, and 2021 is poised to be an even more significant year with preparations underway for the filing of our first base editing Investigational New Drug application. Kate’s unique insights into delivering care for patients in need will be invaluable as we partner with leading clinical investigators and institutions to advance base editing as a novel class of precision genetic medicines.”

    “Having seen firsthand the challenges and hardships that people living with serious or untreatable diseases experience, I am highly encouraged by Beam’s potential to deliver novel, one-time treatments that transform lives,” said Ms. Walsh. “The company’s scientific platform and precision medicine approach could make an impact for so many. I look forward to helping drive this company forward and to partnering with the esteemed Beam team and board of directors on the meaningful milestones ahead.”

    Ms. Walsh has extensive experience leading esteemed healthcare organizations. Prior to her appointment at BMC, Ms. Walsh served as executive vice president and chief operating officer of Brigham and Women's Hospital. She previously served as the chief operating officer for Novartis Institutes for Biomedical Research and at Massachusetts General Hospital (MGH) in positions including senior vice president of medical services at the MGH Cancer Center. Prior to her tenure at MGH, she held positions in a number of New York City hospitals, including Montefiore, Columbia Presbyterian Medical Center, Saint Luke’s - Roosevelt Hospital Center and the New York City Health and Hospitals Corporation. Ms. Walsh holds a B.A. and a master’s degree in public health from Yale University. She is a member of the boards of the Federal Reserve Bank of Boston, the Boston Public Health Commission, the Massachusetts Hospital Association, the AAMC Council of Teaching Hospitals, Pine Street Inn and Yale University.

    About Beam Therapeutics
    Beam Therapeutics (Nasdaq: BEAM) is a biotechnology company developing precision genetic medicines through the use of base editing. Beam’s proprietary base editors create precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the DNA. This enables a wide range of potential therapeutic editing strategies that Beam is using to advance a diversified portfolio of base editing programs. Beam is a values-driven organization committed to its people, cutting-edge science, and a vision of providing life-long cures to patients suffering from serious diseases. For more information, visit www.beamtx.com.

    Forward Looking Statements
    This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Investors are cautioned not to place undue reliance on these forward-looking statements, including, but not limited to, statements related to: the expected timing for filing our first base editing investigational new drug application, and activities related thereto; and the therapeutic applications and potential of our technology, including our ability to develop one-time, life-long, curative, precision genetic medicines for patients through base editing. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement, including, without limitation, risks and uncertainties related to: our ability to develop, obtain regulatory approval for, and potentially commercialize our product candidates, which may take longer or cost more than planned; our ability to raise additional funding, which may not be available; our ability to obtain, maintain and enforce patent and other intellectual property protection for our product candidates; the potential impact of the COVID-19 pandemic; that preclinical testing of our product candidates and preliminary or interim data from preclinical and clinical trials may not be predictive of the results or success of ongoing or later clinical trials; that enrollment of our clinical trials may take longer than expected; that our product candidates may experience manufacturing or supply interruptions or failures; risks related to competitive products; and the other risks and uncertainties identified under the heading “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019, our Quarterly Report on Form 10-Q for the quarters ended March 31, 2020, June 30, 2020, and September 30, 2020, and in any subsequent filings with the Securities and Exchange Commission. These forward-looking statements (except as otherwise noted) speak only as of the date of this press release. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

    Contacts:

    Investors:
    Chelcie Lister
    THRUST Strategic Communications
    [email protected] 

    Media:
    Dan Budwick
    1AB
    [email protected]  


    Get the next $BEAM alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $BEAM

    DatePrice TargetRatingAnalyst
    3/28/2025$42.00Neutral → Buy
    BofA Securities
    3/10/2025$40.00Sector Perform → Sector Outperform
    Scotiabank
    1/29/2025Neutral → Overweight
    Cantor Fitzgerald
    11/6/2024$27.00 → $39.00Market Perform → Outperform
    Leerink Partners
    10/16/2024Sector Outperform
    Scotiabank
    7/23/2024$80.00Buy
    H.C. Wainwright
    1/29/2024$38.00 → $40.00Neutral → Overweight
    JP Morgan
    12/15/2023$35.00Buy → Neutral
    BofA Securities
    More analyst ratings

    $BEAM
    SEC Filings

    See more
    • Beam Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - Beam Therapeutics Inc. (0001745999) (Filer)

      7/3/25 4:30:15 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Beam Therapeutics Inc. (0001745999) (Filer)

      6/6/25 4:05:16 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Beam Therapeutics Inc.

      SCHEDULE 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      5/15/25 5:04:40 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Medical Officer Simon Amy sold $23,962 worth of shares (1,250 units at $19.17), decreasing direct ownership by 2% to 64,864 units (SEC Form 4)

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      7/3/25 5:30:05 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Walsh Kathleen E

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      6/6/25 4:05:30 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Shaw Christi

      4 - Beam Therapeutics Inc. (0001745999) (Issuer)

      6/6/25 4:05:26 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

      Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

      6/13/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease

      CAMBRIDGE, Mass., June 03, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-101, an investigational genetically modified cell therapy for the treatment of sickle cell disease (SCD). "Sickle cell disease is a devasting disorder that affects approximately 100,000 people in the U.S., leading to anemia, severe pain, stroke and even early death. Receiving orphan drug designation from the FDA emphasizes the importance of new treatment options for this debilitating disease, a

      6/3/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to BEAM-302 for the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)

      CAMBRIDGE, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the United States (U.S.) Food and Drug Administration (FDA) has granted orphan drug designation to BEAM-302, a liver-targeting lipid-nanoparticle (LNP) formulation of a guide RNA and an mRNA encoding a base editor designed to correct the disease-causing mutation in patients with alpha-1 antitrypsin deficiency (AATD). AATD is an inherited genetic disorder that affects the lungs and/or liver, leading to early onset emphysema and liver disease, and for which there is significant unmet need for effecti

      5/29/25 4:01:00 PM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Beam Therapeutics upgraded by BofA Securities with a new price target

      BofA Securities upgraded Beam Therapeutics from Neutral to Buy and set a new price target of $42.00

      3/28/25 8:10:19 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics upgraded by Scotiabank with a new price target

      Scotiabank upgraded Beam Therapeutics from Sector Perform to Sector Outperform and set a new price target of $40.00

      3/10/25 11:54:09 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics upgraded by Cantor Fitzgerald

      Cantor Fitzgerald upgraded Beam Therapeutics from Neutral to Overweight

      1/29/25 7:35:38 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Leadership Updates

    Live Leadership Updates

    See more
    • Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer

      CAMBRIDGE, Mass., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Sravan K. Emany as chief financial officer (CFO), effective December 19, 2024. Mr. Emany brings to Beam a breadth of global operational, commercial and financial experience with multinational public corporations and financial institutions. He most recently served as CFO and chief operating officer at Ironwood Pharmaceuticals, Inc. "Beam has built a strong financial position to advance our portfolio of genetic medicines, and Sravan has an exceptional background to lead our capital fo

      12/6/24 7:00:00 AM ET
      $ASRT
      $BEAM
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader

      CAMBRIDGE, Mass., Dec. 04, 2024 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Chirfi Guindo, chief marketing officer of Human Health at Merck & Co., Inc., to its board of directors. Mr. Guindo is a seasoned executive in the pharmaceutical industry and has been a key leader at Merck for more than 25 years, where he held senior executive roles spanning global strategy, commercial operations and leadership in healthcare solutions. "We are thrilled to welcome Chirfi to our board, bringing in yet another exceptionally talented and experienced biopharma leader to o

      12/4/24 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Appoints Biotech Executive Christi Shaw to its Board of Directors

      CAMBRIDGE, Mass., Dec. 14, 2023 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the appointment of Christi Shaw to the company's board of directors. "Christi is an inspiring leader who knows firsthand what it takes to transform cutting-edge science into practice-changing commercial treatment options, most recently building and scaling the industry's premier autologous cell therapy company as CEO of Kite," said John Evans, chief executive officer of Beam Therapeutics. "Her experience leading the transformation of novel science into approved medicines, coupled with her unwavering d

      12/14/23 6:30:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Financials

    Live finance-specific insights

    See more
    • Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 Supporting Differentiated Profile in Sickle Cell Disease (SCD) at European Hematology Association (EHA) 2025 Congress

      Updated Data from 17 Patients Consistent with Previously Presented Data; All Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to <40%, and Resolution of Anemia Patients Required a Median of One Mobilization Cycle and Experienced Rapid Neutrophil and Platelet Engraftment Safety Profile Remained Consistent with Busulfan Conditioning, Autologous Hematopoietic Stem Cell Transplantation and Underlying SCD Enrollment Complete in Both Adult and Adolescent Cohorts of the BEACON Trial, with 30 Patients Expected to be Dosed by Mid-2025 Beam to Host Investor Webcast Today, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., June 13, 2025 (GL

      6/13/25 7:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics to Highlight New Data from BEAM-101 Program in Sickle Cell Disease at European Hematology Association (EHA) 2025 Congress

      Presentation to Include Updated Data from 17 Sickle Cell Disease Patients in the Ongoing BEACON Phase 1/2 Clinical Trial Evaluating Safety and Efficacy of BEAM-101 Beam to Host Investor Webcast on Friday, June 13, 2025, at 4:00 p.m. ET CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (NASDAQ:BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present new data from the BEACON Phase 1/2 clinical trial of BEAM-101 in sickle cell disease (SCD) at the European Hematology Association 2025 Congress (EHA2025), taking place June 12-15, 2025, in Milan, Italy. BEAM-101 is an investigational ge

      5/14/25 9:30:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Beam Therapeutics Announces Positive Initial Data for BEAM-302 in the Phase 1/2 Trial in Alpha-1 Antitrypsin Deficiency (AATD), Demonstrating First Ever Clinical Genetic Correction of a Disease-causing Mutation

      Single Dose of BEAM-302 Led to Durable, Dose-dependent Increases in Total and Functional Alpha-1 Antitrypsin (AAT), Production of Corrected M-AAT, and Decreases in Mutant Z-AAT in Circulation Across Initial Three Dose Levels Third Dose Level of BEAM-302 (60 mg, N=3) Achieved Mean Total AAT of 12.4µM at Day 28, Exceeding Protective Therapeutic Threshold, and Reduced Mutant Z-AAT up to 78% Initial Safety Findings Demonstrated BEAM-302 was Well Tolerated at All Dose Levels with No Serious Adverse Events or Dose-Limiting Toxicities Observed Clinical Profile Supports Continued Dose Escalation, with Updated Data from Part A of the Phase 1/2 Trial Expected to be Presented at Medical Conference

      3/10/25 6:00:00 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $BEAM
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      11/12/24 9:50:15 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      11/7/24 9:56:02 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Beam Therapeutics Inc.

      SC 13G/A - Beam Therapeutics Inc. (0001745999) (Subject)

      10/17/24 11:50:15 AM ET
      $BEAM
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care